Full Library
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
Resource type
Journal Article
Authors/contributors
- Reinwald, M. (Author)
- Silva, J.T. (Author)
- Mueller, N.J. (Author)
- Fortún, J. (Author)
- Garzoni, C. (Author)
- de Fijter, J.W. (Author)
- Fernández-Ruiz, M. (Author)
- Grossi, P. (Author)
- Aguado, J.M. (Author)
Title
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)
Abstract
Background: The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biologic therapies.
Publication
Clinical Microbiology and Infection
Date
06/2018
Volume
24
Pages
S53-S70
Journal Abbr
Clinical Microbiology and Infection
Accessed
6/3/21, 10:15 AM
ISSN
1198743X
Short Title
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies
Language
en
Library Catalog
DOI.org (Crossref)
Citation
Reinwald, M., Silva, J. T., Mueller, N. J., Fortún, J., Garzoni, C., de Fijter, J. W., Fernández-Ruiz, M., Grossi, P., & Aguado, J. M. (2018). ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clinical Microbiology and Infection, 24, S53–S70. https://doi.org/10.1016/j.cmi.2018.02.009
GUIDELINES
HEME-ONC AND CELLULAR THERAPIES
Link to this record